Latest news

  • 11 May 2023
    SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
    SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
  • 02 May 2023
    New Publication Compares Total Vials of CroFab® and Anavip® Administered to Treat US Rattlesnake Envenomation
    Analysis shows patients treated with CroFab require fewer total vials of antivenom, and fewer administrations to achieve control, than Anavip.
  • 15 March 2023
    New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate elimination
    Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomes West Conshohocken, PA, 15 March 2023:  BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze® (glucarpidase) for treating adult patients in the United States who […]

News archive



    You are leaving the global corporate website
    This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
    Choose your region